# 



## 

## 



## 

## 



## 



## 

## 

## 

## 

## 

## 



## 


## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 



## 

## 

## 

## 

## 



## 

## 

## 

## 

## 



## 

## 

## 



## 

## 

## 

## 

## 

## 

|publications<br>and events|this year ca|n be|found below:||||
|---|---|---|---|---|---|---|
|Events|||Publications||||
|Global launch: Delivering|prevention|in|A window ofopportunity:||Delivering||
|an a ein<br>world|||revention|in an a ein|world||
|Delivering<br>prevention<br>in <br>world —Global summit|an ageing||Doctor's orders: Why adherence<br>is critical<br>to improving<br>health outcomes across the<br>life course||||
|The Health and Care Reception—|||||||
|Labour party Conference|||||||
|Leaving no one behind: Ending|||||||
|inequalities<br>in healthcare|—Labour||||||
|art<br>Conference|||||||





|The Health and Care Reception—||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|Conservative<br>Party Conference||||||||||||||||
|LevelLing<br>Up: Ending inequalities|in|||||||||||||||
|healthcare<br>—Conservative<br>Party||||||||||||||||
|Conference||||||||||||||||
|Vaccines and vacation: The role played||||||||||||||||
|by immunisation<br>in getting tourism||||||||||||||||
|movin<br>a ain||||||||||||||||
|Trial and Error' .Supporting<br>age diversity||||||||||||||||
|in clinical trials||||||||||||||||
|Healthy ageing<br>in Israel and the UK:||||||||||||||||
|What can we learn from each other7||||||||||||||||
|Getting to grips with ageing: Can|Japan|||||||||||||||
|and the UK learn from each other7||||||||||||||||
|Pandemics<br>and longevity:<br>Will we die,||||||||||||||||
|survive, or thrive next time7||||||||||||||||
|Report launch<br>—Moving the needle:||||||||||||||||
|Improving<br>uptake ofadult vaccination||||||||||||||||
|in Ja an||||||||||||||||
|Report launch<br>—Trial and error:||||||||||||||||
|Su<br>ortin<br>a e diversi<br>in clinical||trials||||||||||||||
|Moving the margins:<br>Improving|||Moving the|||margins:||||Improving|||adult|||
|pneumococcal<br>vaccine uptake<br>in|||pneumococcai.||||vaccine||||uptake||in|||
|mar<br>inalised<br>rou s|||mar|inalised|||rou||s|||||||
||||European||Pneumococcal|||||||Vaccination:|||A|
||||Pro|ress|Re ort|||||||||||
||||Moving the|||needle:|||Improving||||uptake||of|
||||adult|vaccination||||in|Ja||an|||||
|Events|||Publications|||||||||||||
|The future oftowns and cities—<br>Conservative<br>party Conference|||The Mayhew<br>Review —Future-proofing<br>retirement<br>l.iving; Easing the care and<br>housin<br>crises|||||||||||||
|Events|||Publications|||||||||||||
|Breakfast with Guy Opperman<br>MP,||||||||||||||||
|Minister for Pensions||||||||||||||||
|Health equals wealth<br>—The economic||||||||||||||||
|impact of healthy<br>ageing across Asia||||||||||||||||
|Pacific||||||||||||||||
|Longevity<br>—the missing<br>link in the||||||||||||||||
|climate change debate7||||||||||||||||
|Expert roundtable:<br>Maximising<br>the||||||||||||||||
|economic opportunities<br>ofageing||in||||||||||||||
|Portu<br>al||||||||||||||||
|Growing the longevity<br>economy;|||Health equals||||wealth:||||Maximising|||the||
|Advancing<br>equity and health for|||longevity||dividend||||in Argentina|||||||
|sustained success||||||||||||||||
||||Health equals||||wealth:||||Maximising|||the||
||||longevity||dividend||||in Brazil.|||||||
||||Health equals||||wealth,||||Maximising|||the||
||||longevity||dividend||||in the|||US||||





|||||||Health equals|wealth,|Maximising|the|
|---|---|---|---|---|---|---|---|---|---|
|||||||longevity<br>dividend<br>in||Canada||
|||||||Health equals|wealth:|Maximising|the|
|||||||longevity<br>dividend<br>in||Mexico||
|||||||Health equals|wealth:|Maximising|the|
|||||||longevity<br>dividend<br>in||South Korea||
|||||||Health equals|wealth:|Maximising|the|
|||||||longevity<br>dividend<br>in||Australia||
|||||||Health equals|wealth:|Maximising|the|
|||||||longevity<br>dividend<br>in||Indonesia||
|||||||Health equals|wealth:|Maximising|the|
|||||||longevity<br>dividend<br>in||China||
|||||||Health equals|wealth:|Maximising|the|
|||||||longevity<br>dividend<br>in||Japan||
|||||||Health equals|wealth,|Maximising|the|
|||||||longevity<br>dividend<br>in||South Africa||
|||||||Health equals|wealth:|Maximising|the|
|||||||longevity<br>dividend<br>in||India||
|||||||Health equals wealth: Maximising<br>the<br>longevity<br>dividend<br>across the G2o-||||
|||||||Arabic version||||
|||||||Health equals|wealth:|Maximising|the|
|||||||longevity<br>dividend<br>in||Turkey||
|Events||||||Publications||||
|Report launch: Spending<br>with dementia||||||||||
|—Making the||high|street dementia-|||Retail therapy|—Dementia<br>and spending|||
|friendl||||||||||
|Roundtable:|Enabling|||and protecting||||||
|consumers|with dementia|||||||||
|Demographic||dividends|||—grasping the|||||
|retail. opportunities|||of|healthy ageing||||||
|Report launch||8 reception: Health of||||||||
|Older People||in Places|||—Taking a|Health and place: How level.ling up health||||
|place-based||approach|||to supporting|can keep older workers working||||
|lon<br>er workin||lives||||||||
|||||||HOPE project|report|—Health and|place;|
|||||||How level.ling|up health can keep||older|
|||||||workers<br>workin||||
|||||||HOPE policy|brief —Health and place:|||
|||||||How levelling|up health can keep||older|
|||||||workers<br>workin||||
|||||||Work for tomorrow:<br>Can innovation||||
|||||||support<br>work|in an ageing worid7|||
|Events||||||Publications||||
|Are we still|unprepared||||for ageing?|||||
|Fireside chat||||||||||
|ILC-UK's Autumn|||Reception|||||||
|Future ofAgeing|||2022',||A vision for the|||||
|next 25years||||||||||





## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 

## 



## 

## 

## 



## 




## 

## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 



## 

## 

## 

## 



## 

## 

## 



## 

|||||Unrestricted|Restricted|Total|Total|
|---|---|---|---|---|---|---|---|
|||||funds|funds|2023|2022|
||||Notes|||E|E|
|Income||||||||
|Incoming Resources|from generated||funds|||||
|Voluntary<br>income||||||||
|Grants and donations|||2|12,905|898,716|911,621|738,625|
|Income from other trading||activities;||||||
|Consultancy|||3|361,554||361,554|236,695|
|Other|||3||||118|
|investment<br>Income|||4|1,954||1,954|101|
|Total Income||||376,413|898,716|1,275,329|975,539|
|Expenditure:||||||||
|Charitable<br>activities|||5,6|145,687|700,658|846,345|964,367|
|Administration||||133,902||133,902|128,022|
|Raising Funds||||25,278||25,278|25,000|
|||||304,867|700,658|1,005,525|1,117,389|
|Net income/(expenditure)||and net||||||
|movement<br>in funds|forthe|year||71,546|198,058|269,604|(141,850)|
|Corporation<br>Tax||||x6||t6||
|Reconciliation<br>offunds||||||||
|Total funds brought|forward|||409,131||409,131|550,981|
|Total funds carried|forward|||480,677|198,058|678,719|409,131|





## 

||Notes||Group||Charity|
|---|---|---|---|---|---|
|||2023|2022|2023|2022|
|||E|E|F.|F.|
|FIXEDASSETS||||||
|Tangible assets|||836|||
|INVESTMENTS||||||
|||o|836|||
|CURRENT ASSETS||||||
|Debtors|9|297,728|295,897|434,985|257,494|
|Cash at bank and in hand||531,514|337,923|359,687|321,721|
|||829,242|633,820|794,672|579,215|
|CREDITORS||||||
|Amounts<br>faliing due within one<br>year|10|(150,523)|(225,525)|(115,987)|(170,883)|
|NET CURRENT ASSETS||678,719|408,295|678,685|408,333|
|TOTAL ASSETSLESS||||||
|CURRENT LIABILITIES||678719|409131|678,686|408,334|
|FUNDS||||||
|Restricted funds||||||
|Unrestricted<br>funds||678,719|409,131|678,686|408,334|
|||678,719|409,131|678,686|408,334|





|arch 2023||||||||
|---|---|---|---|---|---|---|---|
||||Notes||Group||Charity|
|||||2023|2022|2023|2022|
|||||f|f|f|f|
|Net Incoming/(outgoing)|resources|||||||
|for the year||||269,604|(141,850)|270,368|(140,871)|
|Adjustments<br>for:||||||||
|Depreciation<br>charges||||836|979|||
|Total Adjustments||||836|979|||
|Cash flows from movements||in||||||
|Debtors/Creditors:||||||||
|(Increase)/decrease<br>in debtors||||(1,831)|(205,930)|(177,491)|(77,033)|
|Increase/(decrease)<br>in creditors||||(75,018)|(40,959)|(54,896)|(94,436)|
|Change<br>in cash and cash|equivalents|||||||
|in the reporting<br>period||||193,591|(387,760)|37,981|(312,340)|
|Cash and cash equivalents|at the beginning|||||||
|ofthe reporting<br>period||||337,923|725,683|321,721|634,062|
|Change<br>in cash and cash equivalents||||193,591|(387,760)|37,981|(312,340)|
|Cash and cash equivalents||at the end||||||
|ofthe reporting<br>period||||531,514|337,923|359,687|321,721|





## 

## 



## 

|2.<br>Grants and Don<br>Funders|atio|ns|||||||
|---|---|---|---|---|---|---|---|---|
||||||Unrestricted|Restricted|Total|Total|
||||||funds|funds|2023|2022|
|||||||f|8|f|
|ABRDN||||||36,563|36,563||
|Alzheimer's<br>Society||||||943|943|525|
|Amgen||||||70,000|70,000|60,000|
|ARCO||||||3,800|3,800|23,700|
|British High Commission||(FCDO)||||19,625|19,625|0|
|Canterbury<br>University||||||||2,500|
|City University<br>of London||||||23,000|23,000|14,000|
|Coal,ition for Life-Course||Immunisation||||23,882|23,882|2g,603|
|Centre for the Study|of|Financial Innovation||||||3,750|
|EY||||||16,950|16,950|16,950|
|Edinburgh<br>University|||||2,200||2,200||
|Foundation<br>ofSocial|Survey Co-op|||||||953|
|Gtaxo Smith Kline||||||177,340|177,340||
|Hallmark||||||35,000|35,000||
|ILC Global. Alliance|||||4,200||4,200|3,539|
|Innovation<br>Resource|Centre for Human||Reso|urces||5,392|5,392|25,344|
|Institute ofActuaries||||||16,000|16,000||
|Legal.5General|||||1,000||1,000|500|
|Merck Sharp 8 Dhome||Corp||||114,074|1.14,074||
|Merck Sharp<br>It.Dhome||(UK) Ltd|||||0|25,965|
|Pfizer|||||4,252|118,775|123,027|222,496|
|RBWConsultancy||||||7,500|7,500||
|Royal College ofArt||||||700|700||
|Sanofi Aventis Groupe||||||71,250|71,250|50,000|
|Standard<br>Life Foundation||||||||66,ooo|
|Stripe Partners||||||3,850|3,850||
|Sundry donations|||||1,253||1,253|389|
|University<br>College London||||||20,890|20,890|3,926|
|University ofSterling||||||133,182|133,182||
|Vaccine Confidence|Fund|||||||188,485|
||||||12,905|898,718|911,821|738,625|
|Previous year|||||||||
|Total|||||7,663|730,962||738,625|





## 

||||||2023|2022|
|---|---|---|---|---|---|---|
||||||E|E|
|Turnover|||||361,554|z36,6g5|
|Cost ofsales|||||||
|Gross profit|||||361,554|z36,695|
|Other income||||||118|
|Administrative<br>expenses,|||including|gift aid|(36z,30z)|(237,792)|
|Corporation<br>Tax|||||(16)||
|Loss for|the year||||(764)|(979)|
|Investment<br>income|||||||
||||||2023|2022|
|Bank interest receivable|||||||
||Expenditure|on|charitable|activities and raising funds|||
||||||2023|2022|
||||||E||
||Project costs||||108,178|332,444|
||Staff costs||||636,825|622,003|
||Travel and|subsistence|||43,021|7,061|
||Telephone,|post,|stationery|and office|66,787|14,002|
||Sundries||||g,61z|10,257|
||Governance|costs —audit||fees|7,200|5,700|
||||||871,623|989,367|





## 

|.<br>Sta|ff and Trustee remuneration|||
|---|---|---|---|
|||2023|2022|
|Staff costs;—||E|8|
|Salaries|and other costs|551,068|541,165|
|Pension|costs|25,962|23,404|
|National|Insurance|59,796|47941|
|||636,825|612,510|



|2023|2022|
|---|---|
|Number|Number|



## 

## 




|Net BookValue|||||||||
|---|---|---|---|---|---|---|---|---|
|At 31March 2023|||||||||
|At 31March 2022||||||B(6|||
|8,<br>Tangible assets|||||||||
|||||||Equipment|||
|||||||||E|
|Charity|||||||||
|Cost|||||||||
|At1April2022|and|31March 2023|||||||
|Depreciation|||||||||
|At 1April. 2022|and|31March 2023|||||||
|Net BookValue|||||||||
|At 31March 2022 and 31|||March 2023||||||
|9.<br>Debtors: amounts||falling|due within one year||||||
|||||Group||Charity|||
|||||2023|2022|2023|2022||
|||||E|E|E||E|
|Grants receivable||||211,571|122,970|211,571|122,970||
|Amounts<br>due from|Subsidiary||Company|||213,400|109,770||
|Trade and other debtors||||81,165|156,858|5,022|8,685||
|Project costs||||4,992|16,069|4,992|16,069||
|||||297,728|295,897|434985|257|494|
|10.<br>Creditors: amounts||falling due within one year|||||||
||||Group|||Charity|||
||||2023|2022||2023||2022|
||||||||f|E|
|Trade creditors|||27,080|16,243||7,561||14,801|
|Deferred income|||40,003|70,400||25,003||32,950|
|Other creditors and|accruals||62,675|109,655||62.675||107,155|
|Othertaxes|||20,765|29,227||20,748||15,977|
||||150,523|225,525||115,987||170,883|





## 

## 

||||||||At 31|
|---|---|---|---|---|---|---|---|
|||||At 1|Incoming|Outgoing|March|
|Projects||||April 2022|Resources|Resources|2023|
||||||F|||
|Actuaries<br>Event Series|||||16,000|16,000||
|CLCI Work agreement|||||23,882|23,882||
|Dementia<br>and spending|||||36,563|36,563||
|Dementia<br>Primary 5Community|||Care||943|943||
|Delivering<br>Prevention|||||304,424|304,424||
|Delivering<br>Prevention||in an ageing world|||3,750|3,750||
|Googl.e Boomers|||||3,850|3,850||
|HOPE - Health Foundation|||||20,890|20,890||
|ILC Partner|||||16,950|16,950||
|Lifecourse Immunisation|||||110,000|110,000||
|Longevity ofSporting||Legends|||16,000|16,000||
|Portugai. 's Longevity|Dividend||||19,625|19,625||
|Retail Impact - Healthy||Ageing|||133,182|133,182||
|Shingles<br>Painfully aware|||||119,840|119,840||
|The Mayhew<br>review|||||3,800|3,800||
|Trial and Error|||||7,500|7,500||
|UK Labour Markets|||||7,000|7,000||
|Vaccine Confidence|in Central||and Eastern Europe||48,775|48,775||
|Work for tomorrow|||||5,392|5,392||
||||||898,716|898,716||





## 

|Projects||||At 1April|Incoming|Outgoing|At 31March|
|---|---|---|---|---|---|---|---|
|||||2021|Resources|Resources|2022|
|A Tai.eoftwo dynasties|||||6,ooo|6,000||
|CLCI Work agreement|||||11,493|11,493||
|Generation<br>Vax|||||188,485|188,485||
|Counting<br>the cost of|inequal. ity||||3,750|3,750||
|Delivering<br>prevention|in an ageing world||||60,000|6o,ooo||
|Spending<br>with Dementia|||||66,000|66,ooo||
|Dementia<br>Primary 5 Community|||Care||525|525||
|Global<br>l.ongevity<br>dividend<br>profiles||—Country|||50,000|50,000||
|Health ofOlder People in Places|||(HOPE)||3,926|3,926||
|ILC Partner's<br>Programme|||||16,950|16,950||
|Hitting<br>new Heights|||||18,110|18,110||
|Longevity ofsporting|legends||||8,ooo|8,000||
|Moving the margins|||||37,375|37,375||
|Moving the needle|||||182,839|182,839||
|Nascent Generations|Network||||2,500|2,500||
|Safeguarding<br>healthy|ageing||||25,965|25,965||
|The Mayhew<br>review|||||23,700|23,700||
|Work for Tomorrow|||||25,344|25,344||
||||||730,962|730,962||





## 

|1z,<br>Unrestricted<br>funds||||||
|---|---|---|---|---|---|
|||Charity|Non Charity|2023<br>2022||
|||Funds|Trading|Total|Total|
||||Funds|||
|Balance at 1April 2022||408,334|797|409,131|550,981|
|Net Incoming/(outgoing)<br>year|resources for the|270,352|(764)|269,588|(141,850)|
|Balance at 31March 2023||678,686|33|678,719|409,131|



## 

## 

|Thi|s isstated after charging:|||
|---|---|---|---|
|||2023|2022|
|Depreciation||836|979|
|Auditors'|remuneration|11,200|5,700|





## 

|over the remaining<br>life ofthose|leases off55,8zo izozz —f|gz,939)|||
|---|---|---|---|---|
|||Group||Charity|
||2023|2022|2023|2022|
||f|8||S|
|Within tyear|55,820||||
|2to 5years||9'1,939|||
||55,820|91,939|||



## 

